Search results for "ANEM"

showing 10 items of 405 documents

Erythrocyte deformability in macrocytosis determined by means of ektacytometry techniques

2010

There is little information regarding the behaviour of red blood cell deformability in macrocytosis. We have determined in 114 patients with macrocytosis (MCV > 97 fL) and in 115 age and sex-matched subjects with normocytosis (VCM < 97 fL) erythrocyte deformability by means of ektacytometric techniques (Rheodyn SSD) measuring the erythrocyte elongation index (EEI) at 12, 30 and 60 Pa. Patients with macrocytosis showed statistically higher EEI at all the shear stresses tested when compared with controls (p < 0.001). When patients with macrocytosis were classified according to their main diagnosis as hepatic or renal disease, HIV and miscellaneous, 66.7%, 41.7%, 36.7% and 33.3% of patients, r…

AdultMalemedicine.medical_specialtyPhysiologyBilirubinAnemiaHuman immunodeficiency virus (HIV)NormocytosisMacrocytosismedicine.disease_causeGastroenterologychemistry.chemical_compoundErythrocyte DeformabilityPhysiology (medical)Internal medicinemedicineHumansErythrocyte deformabilityAnemia MacrocyticAlanine aminotransferaseAgedbusiness.industryHematologyMiddle Agedmedicine.diseaseRed blood cellmedicine.anatomical_structurechemistryImmunologyFemaleStress MechanicalCardiology and Cardiovascular MedicinebusinessClinical Hemorheology and Microcirculation
researchProduct

Blood laboratory findings in patients suffering from self-perceived electromagnetic hypersensitivity (EHS)

2009

Risks from electromagnetic devices are of considerable concern. Electrohypersensitive (EHS) persons attribute a variety of rather unspecific symptoms to exposure to electromagnetic fields. The pathophysiology of EHS is unknown and therapy remains a challenge. We hypothesized that some electrosensitive individuals are suffering from common somatic health problems. Toward this end we analysed clinical laboratory parameters including thyroid-stimulating hormone (TSH), alanine transaminase (ALT), aspartate transaminase (AST), creatinine, hemoglobine, hematocrit and c-reactive protein (CRP) in subjects suffering from EHS and in controls that are routinely used in clinical medicine to identify or…

AdultMalemedicine.medical_specialtyPhysiologyBiophysicsThyrotropinAspartate transaminaseHematocritElectromagnetic hypersensitivitychemistry.chemical_compoundElectromagnetic FieldsInternal medicineHypersensitivitymedicineHumansRadiology Nuclear Medicine and imagingIn patientAspartate AminotransferasesAgedInflammationCreatininebiologymedicine.diagnostic_testbusiness.industryLiver DiseasesAlanine TransaminaseAnemiaGeneral MedicineMiddle AgedThyroid DiseasesPathophysiologyC-Reactive ProteinEndocrinologychemistryAlanine transaminaseCreatininebiology.proteinFemalePerceptionmedicine.symptombusinessHormoneBioelectromagnetics
researchProduct

Posttransfusional, LKM-1-autoantibody-positive hepatitis C virus infection, cryoglobulinemia, and aplastic anemia.

1995

Aplastic anemia is occasionally caused by viral hepatitis, hepatitis C virus being the most important factor. Pathogenetically, decreased bone marrow function, abnormalities of the bone marrow microenvironment, and immune-mediated suppression of hematopoiesis are important. Hepatitis C virus infection is associated with a variety of extrahepatic manifestations including autoimmune features like cryoglobulinemia, Sjogren's syndrome, and autoimmune hepatitis. Here we report the case of a 42-year-old man with aplastic anemia due to posttransfusional hepatitis C virus infection associated with cryoglobulinemia and LKM-1 autoantibodies. Following a triple immunosuppressive therapy, there was a c…

AdultMalemedicine.medical_specialtyPhysiologyHepatitis C virusAutoimmune hepatitismedicine.disease_causeBone MarrowInternal medicinemedicineHumansAplastic anemiaAutoantibodiesbusiness.industryGastroenterologyAutoantibodyAnemia AplasticTransfusion ReactionHepatologymedicine.diseaseVirologyCryoglobulinemiaHepatitis Cmedicine.anatomical_structureCryoglobulinemiaImmunologyBone marrowbusinessViral hepatitisDigestive diseases and sciences
researchProduct

Oral high-dose sucrosomial iron vs intravenous iron in sideropenic anemia patients intolerant/refractory to iron sulfate: a multicentric randomized s…

2020

AbstractIron deficiency anemia is among the most frequent causes of disability. Intravenous iron is the quickest way to correct iron deficiency, bypassing the bottleneck of iron intestinal absorption, the only true mechanism of iron balance regulation in human body. Intravenous iron administration is suggested in patients who are refractory/intolerant to oral iron sulfate. However, the intravenous way of iron administration requires several precautions; as the in-hospital administration requires a resuscitation service, as imposed in Europe by the European Medicine Agency, it is very expensive and negatively affects patient’s perceived quality of life. A new oral iron formulation, Sucrosomi…

AdultMalemedicine.medical_specialtyResuscitationIntravenous sodium ferrigluconateAnemiaCost-Benefit AnalysisHigh dosesAdministration OralHigh dose030204 cardiovascular system & hematologyGastroenterologyFerric CompoundsIntestinal absorption03 medical and health scienceschemistry.chemical_compound0302 clinical medicineRefractoryInternal medicineOral Sucrosomial ironMedicineHumans030212 general & internal medicineFerrous CompoundsProspective StudiesAgedAged 80 and overHematologyAnemia Iron-Deficiencybusiness.industryHematologyGeneral MedicineIron deficiencyMiddle Agedmedicine.diseaseIron sulfatechemistryIron-deficiency anemiaIron deficiency anemiaHematinicsAdministration IntravenousFemaleOriginal ArticleRefractoriness/intolerance to oral iron sulfatebusiness
researchProduct

Partial T Cell-Depleted Peripheral Blood Stem Cell Transplantation from HLA-Identical Sibling Donors for Patients with Severe Aplastic Anemia

2019

We analyzed the outcomes of 26 consecutive patients with acquired severe aplastic anemia (SAA) undergoing peripheral blood stem cell transplantation (PBSCT) with partial ex vivo T cell depletion with a targeted T cell dose from HLA-identical sibling donors. The median patient age was 37 years (range, 3 to 63 years). Four patients with uncontrolled pneumonia at the time of transplantation died, on days +1, +2, +21, and +26. All evaluable patients engrafted, with a median time to neutrophil recovery of 11 days (range, 10 to 14 days) and a median time to platelet recovery of 19 days (range, 8 to 53 days). Two patients had transient grade I acute graft-versus-host disease (GVHD) with skin invol…

AdultMalemedicine.medical_specialtySevere aplastic anemiaAdolescentT-LymphocytesT cellGraft vs Host DiseaseHuman leukocyte antigenSeverity of Illness IndexGastroenterologyDisease-Free SurvivalLymphocyte DepletionHLA AntigensInternal medicinemedicineHumansCumulative incidenceSiblingChildAllogeneic stem cell transplantation Ex vivo T cell depletion Matched sibling donor Severe aplastic anemiaEx vivo T cell depletionMatched sibling donorPeripheral Blood Stem Cell TransplantationTransplantationbusiness.industryHistocompatibility TestingSiblingsAnemia AplasticHematologyMiddle AgedAllograftsmedicine.diseaseSevere Aplastic AnemiaTissue DonorsAllogeneic stem cell transplantationSurvival RateTransplantationPneumoniasurgical procedures operativemedicine.anatomical_structureChild PreschoolAcute DiseasebusinessEx vivoFollow-Up StudiesBiology of Blood and Marrow Transplantation
researchProduct

Addition of rituximab to standard therapy improves response rate and progression-free survival in relapsed or refractory thrombotic thrombocytopenic …

2007

SummaryTreatment of relapsed or refractory autoimmune mediated haemolytic syndromes, such as autoimmune haemolytic anaemia (AIHA) and thrombotic thrombocytopenic purpura (TTP), represents a therapeutic challenge. Here we report on our experience with the monoclonal anti-CD20 antibody rituximab (R) compared to standard treatment in these diseases. Patients with non-familialTTP orAIHA and no underlying malignancy were included in our analysis. Safety and efficacy of R-treatment were compared to results obtained in standard treatment approaches. Altogether, 27 patients were analyzed, comprising 15 patients withTTP and 12 patients with AIHA. The patients’ average age at the time of diagnosis wa…

AdultMalemedicine.medical_specialtyTime FactorsThrombotic thrombocytopenic purpuraSalvage therapyGastroenterologyDisease-Free SurvivalAntibodies Monoclonal Murine-DerivedPharmacotherapyRefractoryRecurrenceMedian follow-upGermanyhemic and lymphatic diseasesInternal medicinemedicineHumansImmunologic FactorsProgression-free survivalAgedRetrospective StudiesSalvage TherapyPurpura Thrombocytopenic Idiopathicbusiness.industryStandard treatmentAntibodies MonoclonalHematologyMiddle Agedmedicine.diseaseSurgeryTreatment OutcomeDrug Therapy CombinationFemaleRituximabAnemia Hemolytic AutoimmuneRituximabbusinessFollow-Up Studiesmedicine.drugThrombosis and Haemostasis
researchProduct

Phase 2 Trial of Docetaxel, Gemcitabine, and Oxaliplatin Combination Chemotherapy in Platinum- and Paclitaxel-Pretreated Epithelial Ovarian Cancer

2009

Background: This phase 2 trial was designed to evaluate the efficacy and toxicity of a combination of docetaxel, gemcitabine, and oxaliplatin for platinum- and paclitaxel-pretreated epithelial ovarian cancer. Patients and Methods: Heavily pretreated patients (N = 30; median age, 61 years) received docetaxel, 55 mg/m2; gemcitabine, 500 mg/m2 (day 1); and oxaliplatin, 70 mg/m2 (day 2) biweekly. Twelve patients had platinum-sensitive disease, and 18 patients had platinum-resistant disease. Results: Median follow-up was 18.6 months. No differences in patient characteristics were observed between patients with carboplatinum-sensitive and carboplatinum-resistant disease. In patients with carbopla…

AdultOncologymedicine.medical_specialtyAdolescentOrganoplatinum CompoundsPaclitaxelAnemiaDocetaxelNeutropeniaDeoxycytidineYoung Adultchemistry.chemical_compoundRisk FactorsInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineFallopian Tube NeoplasmsHumansNeoplasm InvasivenessProspective StudiesPeritoneal NeoplasmsAgedNeoplasm StagingOvarian Neoplasmsbusiness.industryObstetrics and GynecologyCombination chemotherapyMiddle AgedPrognosismedicine.diseaseGemcitabineGemcitabineOxaliplatinOxaliplatinTreatment OutcomeOncologyDocetaxelPaclitaxelchemistryFemaleTaxoidsOvarian cancerbusinessmedicine.drugInternational Journal of Gynecological Cancer
researchProduct

Pediatric non-neuronopathic Gaucher disease: presentation, diagnosis and assessment. Consensus statements.

2003

In individuals with non-neuronopathic Gaucher disease, childhood manifestations are usually predictive of a more severe phenotype. Although children with Gaucher disease are at risk of irreversible disease complications, early intervention with an optimal dose of enzyme therapy can prevent the development of complications and ensure adequate, potentially normal, development through childhood and adolescence. Very few, if any, children diagnosed by signs and symptoms should go untreated. Evidence suggests that disease severity, disease progression and treatment response in different organs where glucocerebroside accumulates are often non-uniform in affected individuals. Therefore, serial mon…

AdultPediatricsmedicine.medical_specialtyConsensusBone diseaseAdolescentGenotypeAnemiaHepatosplenomegalyDiseaseGlucocerebrosideCentral nervous system diseaseQuality of lifemedicineHumansChildAgedGaucher Diseasebusiness.industryAge FactorsInfantMiddle Agedmedicine.diseasenon-neuronopathic Gaucher diseaseChild PreschoolPediatrics Perinatology and Child HealthImmunologyQuality of Lifemedicine.symptombusinessGlucocerebrosidaseEuropean journal of pediatrics
researchProduct

Thrombopoietin receptor agonists in adult Evans syndrome: an international multicenter experience.

2022

AdultPurpura Thrombocytopenic IdiopathicRecombinant Fusion ProteinsImmunologySevere thrombocytopeniaCell BiologyHematologyReceptors FcBiochemistryBenzoatesThrombocytopeniaBenzoateThrombocytopenia.HydrazinesThrombopoietinEltrombopagHydrazineHumansAnemia Hemolytic AutoimmuneReceptors ThrombopoietinHumanRecombinant Fusion ProteinBlood
researchProduct

Effects of anemia correction with epoetin beta in patients receiving radiochemotherapy for advanced cervical cancer

2007

Patients with cervical cancer frequently suffer from anemia. This two-stage, adaptive-design study investigated the effect of anemia correction with epoetin beta on treatment outcomes. Patients with stage IIB–IVA cervical cancer received radiochemotherapy (RCT) and were randomized to epoetin 150 IU/kg three times weekly (n = 34) or standard care (control; n = 40) for up to 12 weeks. Primary end point for stage 1 aimed to establish a correlation between anemia correction and treatment failure (no complete response or relapsing within 6 months after RCT initiation) as a proof of concept before moving into stage 2. Secondary end points included progression/relapse-free survival, overall surviv…

Adultmedicine.medical_specialtyAnemiaInjections Subcutaneousmedicine.medical_treatmentUterine Cervical NeoplasmsRisk AssessmentGastroenterologyDrug Administration Schedulelaw.inventionRandomized controlled trialReference ValueslawInternal medicinemedicineClinical endpointHumansAdverse effectErythropoietinSurvival analysisNeoplasm StagingProbabilityCervical cancerChemotherapyEpoetin betaDose-Response Relationship Drugbusiness.industryObstetrics and GynecologyAnemiaMiddle Agedmedicine.diseaseCombined Modality TherapyImmunohistochemistrySurvival AnalysisRecombinant ProteinsSurgeryLogistic ModelsTreatment OutcomeOncologyChemotherapy AdjuvantFemaleRadiotherapy AdjuvantbusinessFollow-Up StudiesInternational Journal of Gynecologic Cancer
researchProduct